Published in Nature on September 04, 2008
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
The cancer genome. Nature (2009) 23.13
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet (2010) 11.82
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet (2010) 10.71
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Charting a course for genomic medicine from base pairs to bedside. Nature (2011) 9.39
The case for cloud computing in genome informatics. Genome Biol (2010) 9.20
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Predicting the functional effect of amino acid substitutions and indels. PLoS One (2012) 8.61
Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet (2011) 8.53
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
The transcriptional network for mesenchymal transformation of brain tumours. Nature (2009) 8.44
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Visualizing genomes: techniques and challenges. Nat Methods (2010) 6.66
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell (2011) 5.75
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst (2011) 5.09
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One (2009) 5.08
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
A human functional protein interaction network and its application to cancer data analysis. Genome Biol (2010) 4.73
Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron (2011) 4.66
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 4.63
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data. Database (Oxford) (2011) 4.53
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet (2012) 4.51
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. Nat Protoc (2009) 4.45
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol (2014) 3.99
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep (2013) 3.92
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A (1992) 5.53
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) (2007) 4.04
Alkylation damage in DNA and RNA--repair mechanisms and medical significance. DNA Repair (Amst) (2004) 4.03
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol (1995) 3.53
Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. Anticancer Res (1996) 3.12
Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet (2000) 3.06
Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med (1997) 3.04
Targeted molecular therapy of GBM. Brain Pathol (2003) 3.02
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat (2007) 2.49
Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle (2006) 2.39
Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther (2003) 2.38
Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet (1997) 2.37
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg (2003) 2.24
Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med Chem (2008) 2.16
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int J Cancer (2008) 2.09
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Landscape of somatic retrotransposition in human cancers. Science (2012) 4.37
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76
The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21
Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One (2012) 1.76
Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A (2012) 1.63
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet (2016) 1.16
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06
Integrated genomic and molecular characterization of cervical cancer. Nature (2017) 0.96
Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell (2017) 0.92
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell (2017) 0.81
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell (2017) 0.79
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 0.76
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell (2017) 0.75